UroGen Pharma’s (URGN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $55.00 price objective on the stock. HC Wainwright also issued estimates for UroGen Pharma’s Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at $0.24 EPS and Q4 2026 earnings at $0.54 EPS.

Several other research firms also recently issued reports on URGN. Scotiabank initiated coverage on shares of UroGen Pharma in a research report on Wednesday, April 16th. They issued a “sector outperform” rating and a $23.00 price target for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a research note on Monday, March 10th. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price on the stock. Finally, The Goldman Sachs Group lowered their price target on shares of UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating for the company in a report on Thursday, April 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $32.86.

UroGen Pharma Stock Performance

Shares of UroGen Pharma stock opened at $11.64 on Monday. UroGen Pharma has a fifty-two week low of $8.94 and a fifty-two week high of $20.70. The company’s 50 day moving average price is $10.47 and its two-hundred day moving average price is $11.08. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a market capitalization of $536.53 million, a P/E ratio of -3.70 and a beta of 0.80.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. On average, equities analysts forecast that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling at UroGen Pharma

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now owns 145,666 shares in the company, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On UroGen Pharma

Several institutional investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in UroGen Pharma during the 4th quarter worth $59,000. Lazard Asset Management LLC purchased a new stake in UroGen Pharma during the fourth quarter worth about $67,000. GAMMA Investing LLC lifted its holdings in shares of UroGen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after purchasing an additional 7,392 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of UroGen Pharma in the fourth quarter valued at about $101,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of UroGen Pharma in the fourth quarter valued at about $126,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.